Clinical Trial Update: Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT). [Phase 3]

View source ↗

Summary

Milestone Pharmaceuticals announced termination of a Phase 3 trial evaluating etripamil for termination of spontaneous paroxysmal supraventricular tachycardia, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Supraventricular Tachycardia

Drugs mentioned

• Etripamil (etripamil)

Snippet

Sponsor: Milestone Pharmaceuticals Inc. | Conditions: Paroxysmal Supraventricular Tachycardia | Phase 3 | Status: TERMINATED | Results posted: 2024-07-12